Obagi Medical Products
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Obagi Medical Products met expectations on revenues and crushed expectations on earnings per share.
Compared to the prior-year quarter, revenue increased slightly and GAAP earnings per share improved significantly.
Gross margins expanded, operating margins shrank, net margins expanded.
Obagi Medical Products recorded revenue of $30.6 million. The six analysts polled by S&P Capital IQ predicted net sales of $30.7 million on the same basis. GAAP reported sales were 1.0% higher than the prior-year quarter's $30.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.27. The six earnings estimates compiled by S&P Capital IQ predicted $0.19 per share. GAAP EPS of $0.27 for Q4 were 93% higher than the prior-year quarter's $0.14 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 79.2%, 20 basis points better than the prior-year quarter. Operating margin was 26.8%, 1,260 basis points worse than the prior-year quarter. Net margin was 16.6%, 700 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $28.1 million. On the bottom line, the average EPS estimate is $0.20.
Next year's average estimate for revenue is $121.6 million. The average EPS estimate is $0.89.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 267 members out of 272 rating the stock outperform, and five members rating it underperform. Among 89 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 87 give Obagi Medical Products a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Obagi Medical Products is outperform, with an average price target of $14.50.
The drug and health-care investing landscape is littered with also-rans and a few major winners. Is Obagi Medical Products the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Obagi Medical Products to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.